ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to present at Prion 2017 International Conference
(Thomson Reuters ONE) -
TORONTO and CAMBRIDGE, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- ProMIS
Neurosciences, Inc. (TSX:PMN), a biotechnology company focused on the discovery
and development of precision treatments for neurodegenerative diseases,
announced that Neil Cashman, MD, Chief Scientific Officer and Co-Founder will
present today at PRION 2017, the International Conference Deciphering
Neurodegenerative Disorders in Edinburgh, Scotland.
Dr. Cashman's presentation, entitled Epitope Identification of Toxic Propagating
Strains of Aß Oligomers, describes the use of ProMIS' proprietary discovery
engine to identify targets (epitopes) on toxic prion-like forms of Amyloid beta
oligomers (AßO), considered a root cause of Alzheimer's disease.
Commenting on the presentation, Dr. Cashman stated, "we have been able to raise
antibodies against these epitopes that selectively bind the toxic prion-like
forms of Amyloid beta and block their neurotoxicity and propagation. To date,
two of these antibodies - PMN310 and PMN350 - each selectively addressing a
different target epitope - have been designated as our lead products for
development in Alzheimer's disease."
Organizers of the conference anticipate participation of more than 400
academics, strategists, innovators, policy makers and researchers from public
and private sector across the international field of Prion research. The
14th annual conference will gather attendees to discuss the latest research
being carried out in prion diseases and the broader field of neurodegenerative
diseases and to examine the commonalities and differences between these
devastating diseases.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO),
headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts.
The mission of ProMIS is to discover and develop precision medicine therapeutics
for effective treatment of neurodegenerative diseases, in particular Alzheimer's
disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of
two, complementary techniques. The Company applies its thermodynamic,
computational discovery platform-ProMIS(TM) and Collective Coordinates - to
predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this unique "precision medicine" approach,
ProMIS Neurosciences is developing novel antibody therapeutics and specific
companion diagnostics for Alzheimer's disease and ALS. The company has also
developed two proprietary technologies to specifically identify very low levels
of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences
owns a portfolio of therapeutic and diagnostic patents relating to misfolded
SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic
against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release. This information release may contain certain forward-
looking information. Such information involves known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by statements herein,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on the
Company's current beliefs as well as assumptions made by and information
currently available to it as well as other factors. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties, including the
risks and uncertainties identified by the Company in its public securities
filings, actual events may differ materially from current expectations. The
Company disclaims any intention or obligation to update or revise any forward-
looking statements, whether as a result of new information, future events or
otherwise.
For further information please consult the Company's website at:
www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
For media inquiries, please contact:
Scott Santiamo
RussoPartners/LLC
Scott.Santiamo(at)russopartnersllc.com
Tel. 718 344-5843
David Schull
RussoPartners/LLC
David.Schull(at)russopartnersllc.com
Tel. 858 717-2310
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 25.05.2017 - 13:30 Uhr
Sprache: Deutsch
News-ID 544631
Anzahl Zeichen: 5549
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 243 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to present at Prion 2017 International Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
ProMIS Neurosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
